Strand Therapeutics Inc. — Form D
Strand Therapeutics Inc. of Boston, MA, a company, filed a Form D exempt-offering notice with the SEC on 2026-03-17. The offering totals $120.1M, of which $108.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2026-03-17
- Form: D
- Accession: 0001231919-26-000259
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $120.1M
- Amount sold: $108.1M
- Remaining: $12.0M
- Investors: 10
- Date of first sale: 2025-05-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-576809
Issuer
- Name: Strand Therapeutics Inc.
- CIK: 0001778475
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 20 Overland Street, Boston, MA, 02215
- Phone: 617-993-9271
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Ala Alenazi | Director | Boston, MA |
| Pegah Ebrahimi | Director | Cupertino, CA |
| Jeb Keiper | Director | Boston, MA |
| Samta Kundu | Executive Officer | Boston, MA |
| Jory Bell | Director | Palo Alto, CA |
| Tasuku Kitada | Director | Boston, MA |
| Tasuku Kitada | Executive Officer | Boston, MA |
| Tasuku Kitada | Promoter | Boston, MA |
| Jacob Becraft | Director | Boston, MA |
| Jacob Becraft | Executive Officer | Boston, MA |
| Jacob Becraft | Promoter | Boston, MA |
| Samta Jacob Kundu | Executive Officer | Cambridge, MA |
Other filings by this issuer (2)
More